Dexcom (NSDQ:DXCM) posted second-quarter results this evening that beat the consensus forecast on Wall Street, and raised its outlook for the rest of the year.
The San Diego–based continuous glucose monitoring (CGM) technology company reported a loss of $10.5 million, or $0.12 per share, on sales of $336.4 million for the three months ended June 30. Sales were up 39% compared with Q2 2018, which saw profits of $30.2 million, or $0.34 per share.
Adjusted to exclude one-time items, earnings per share were $0.08, 8¢ ahead of The Street, where analysts were looking for sales of $304.4 million.
Get the full story on our sister site Drug Delivery Business News.